Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 7:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,499 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage II Lung Cancer Clear all
Active, not recruiting Phase 2 Interventional

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

NCT04607954
View directory record Official record
Conditions
Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Refractory Extensive Stage Lung Small Cell Carcinoma
Interventions
Durvalumab, Lurbinectedin
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 7, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

Pharmacological Ascorbate for Lung Cancer

NCT02420314
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 7, 2026, 7:36 AM EDT
Completed Phase 2 Interventional

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00042978
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
oblimersen sodium, carboplatin, etoposide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Sep 7, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

NCT00087438
View directory record Official record
Conditions
Lung Cancer
Interventions
stereotactic body radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
2
States / cities
Rochester, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 7, 2026, 7:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers

NCT03902535
View directory record Official record
Conditions
Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Metastatic Head and Neck Carcinoma, Metastatic Lung Carcinoma, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Comprehensive Geriatric Assessment, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 7, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional Results available

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

NCT04951115
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Carboplatin, Cisplatin, Etoposide, Durvalumab, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Brooklyn, New York • Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 7, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional

Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

NCT00359450
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
BMS-275183 (oral taxane)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
Burlington, Massachusetts • St Louis, Missouri • Morganton, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 7, 2026, 7:36 AM EDT
Not listed Early Phase 1 Interventional

Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management

NCT06060964
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage I, Lung Cancer Stage II, Lung Cancer Stage III
Interventions
Breathe Easier Progressive Web Application
Other
Lead sponsor
University of South Carolina
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 7, 2026, 7:36 AM EDT
Terminated Not applicable Interventional

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

NCT00087191
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
EF5, motexafin lutetium, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 7, 2026, 7:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

NCT07538804
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ANS02
Drug
Lead sponsor
Avistone Biotechnology Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 7, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

NCT01262820
View directory record Official record
Conditions
Lung Cancer
Interventions
Pazopanib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 7, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional Results available

Liver Directed RT + Chemo-immunotherapy for ES-SCLC

NCT04923776
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
Carboplatin, Etoposide, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Brian Henick, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Sep 7, 2026, 7:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

NCT02963610
View directory record Official record
Conditions
Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
Interventions
Lenalidomide, Pembrolizumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 7, 2026, 7:36 AM EDT
Recruiting Phase 2 Interventional

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

NCT06769126
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
148
States / cities
Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 7, 2026, 7:36 AM EDT
Completed Phase 2 Interventional

Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

NCT00010218
View directory record Official record
Conditions
Lung Cancer
Interventions
karenitecin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
44
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Sep 7, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional Results available

Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain

NCT00550654
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy, image-guided radiation therapy, tomotherapy
Other · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 7, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00528645
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Lung Metastases, Malignant Pleural Effusion, Recurrent Small Cell Lung Cancer
Interventions
saracatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 7, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel

NCT02684461
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Sep 7, 2026, 7:36 AM EDT
Recruiting Phase 2 Interventional

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

NCT06623656
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cemiplimab, Platinum based chemotherapy, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 7, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional Results available

Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease

NCT02469701
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Metastatic Lung Cancer, NSCLC
Interventions
nivolumab and ablation
Drug
Lead sponsor
howard safran
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 7, 2026, 7:36 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

NCT04334941
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
561
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 7, 2026, 7:36 AM EDT
Completed Phase 2 Interventional

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

NCT01496742
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Placebo, RO5490258, bevacizumab [Avastin], cisplatin/carboplatin, paclitaxel, pemetrexed
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
32
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 7, 2026, 7:36 AM EDT
Completed Phase 2 Interventional Results available

BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

NCT00410059
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 7, 2026, 7:36 AM EDT
Recruiting Phase 2 Interventional

A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest

NCT05354570
View directory record Official record
Conditions
Thymic Malignancies, Pleural Metastases
Interventions
Intensity-Modulated Pleural Radiation Therapy (IMPRINT)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 7, 2026, 7:36 AM EDT